Analystreport

UroGen Pharma Ltd. (NASDAQ: URGN) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $40.00 price target on the stock.

UroGen Pharma Ltd. - Ordinary Shares  (URGN) 
Last urogen pharma ltd. - ordinary shares earnings: 3/2 08:00 am Check Earnings Report
US:NASDAQ Investor Relations: investors.urogen.com